BR112012008946A2 - sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina - Google Patents

sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina

Info

Publication number
BR112012008946A2
BR112012008946A2 BR112012008946A BR112012008946A BR112012008946A2 BR 112012008946 A2 BR112012008946 A2 BR 112012008946A2 BR 112012008946 A BR112012008946 A BR 112012008946A BR 112012008946 A BR112012008946 A BR 112012008946A BR 112012008946 A2 BR112012008946 A2 BR 112012008946A2
Authority
BR
Brazil
Prior art keywords
vaccine
virus
vaccines
ttv
pollinucleotide
Prior art date
Application number
BR112012008946A
Other languages
English (en)
Inventor
Donna Steuerward Dunyak
Douglas Steven Pearce
Gregory Paul Nitzel
Jacqueline Gayle Marx
James Richard Thompson
Jay Gregory Calvert
Mira Ivanova Stoeva
Nancee Lois Oein
Robert Gerard Ankenbauer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority claimed from PCT/US2010/031373 external-priority patent/WO2011046634A1/en
Publication of BR112012008946A2 publication Critical patent/BR112012008946A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

clones infecciosos de vírus torque teno a presente invenção refere-se a novas sequências nucleotídicas e de aminoácidos do vírus torque teno ("ttv") , incluindo novos genótipos do mesmo, todas as quais sejam úteis na preparação de vacinas para tratar e prevenir doanças em suínos e outros animais. as vacinas fornecidas de acordo com a prática da invenção são eficazes contra múltiplos genótipos e isolados suínos de ttv. anticorpos policlonais e monoclonais diagnósticos e terapêuticos são também uma características da presente invenção, uma vez que são clones infecciosos úteis na propagação do vírus e na preparação de vacinas. aspectos particularmente importantes da invenção incluem vacinas qiue fornecem proteína da orf1 de ttv, ou fragmentos peptídicos da mesma, como antígenos. aspectos particularmente importantes da invenção incluem vacinas que fornecem proteína da orf1 de ttv, ou fragmentos peptídicos da mesma , como antígeno.
BR112012008946A 2008-10-16 2010-04-16 sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina BR112012008946A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19646808P 2008-10-16 2008-10-16
PCT/US2009/005662 WO2010044889A2 (en) 2008-10-16 2009-10-16 Torque teno virus (ttv) isolates and compositions
PCT/US2010/031373 WO2011046634A1 (en) 2009-10-16 2010-04-16 Infectious clones of torque teno virus

Publications (1)

Publication Number Publication Date
BR112012008946A2 true BR112012008946A2 (pt) 2016-08-16

Family

ID=42107116

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0920248A BRPI0920248A2 (pt) 2008-10-16 2009-10-16 isolados e composicoes do virus torque teno(ttv)
BR112012008946A BR112012008946A2 (pt) 2008-10-16 2010-04-16 sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0920248A BRPI0920248A2 (pt) 2008-10-16 2009-10-16 isolados e composicoes do virus torque teno(ttv)

Country Status (11)

Country Link
US (3) US8969536B2 (pt)
EP (1) EP2356132A2 (pt)
JP (1) JP2012505653A (pt)
KR (3) KR20130126755A (pt)
CN (1) CN102256997A (pt)
AU (1) AU2009303845B2 (pt)
BR (2) BRPI0920248A2 (pt)
CA (1) CA2739469A1 (pt)
MX (1) MX2011004053A (pt)
RU (2) RU2502801C2 (pt)
WO (1) WO2010044889A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127279A2 (en) * 2006-10-05 2008-10-23 Cerebus Biologicals, Inc. Methods for treating, preventing and diagnosing porcine ttv infection
EP2356132A2 (en) 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
RU2553223C2 (ru) 2009-08-21 2015-06-10 Виргиния Тек Интеллекчуал Пропертиз, Инк. ВАКЦИНЫ НА ОСНОВЕ СВИНОГО ВИРУСА Torque teNO И СПОСОБЫ ДИАГНОСТИКИ ИНФЕКЦИЙ, ВЫЗВАННЫХ ЭТИМ ВИРУСОМ
US9249192B2 (en) 2009-08-21 2016-02-02 Virginia Tech Intellectual Properties, Inc. Infectious genomic DNA clone and serological profile of Torque teno sus virus 1 and 2
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
CN103865955A (zh) * 2009-10-16 2014-06-18 佐蒂斯有限责任公司 细环病毒的感染性克隆
EP2530170A1 (en) * 2011-05-31 2012-12-05 Intervet International BV Torque Teno virus diagnostics
WO2012168818A1 (en) * 2011-06-08 2012-12-13 Ah Usa 42 Llc Infectious clones of torque teno virus
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN102998453B (zh) * 2012-11-23 2014-10-08 广东海大畜牧兽医研究院有限公司 一种猪Ⅰ型细环病毒TTSuV1抗体间接ELISA诊断试剂盒及其制备方法
CN103205511B (zh) * 2013-04-27 2014-08-27 金陵科技学院 一种用于检测鸽细环病毒的引物对及其应用
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
CN106867972A (zh) * 2015-12-11 2017-06-20 上海交通大学医学院附属第九人民医院 小细环病毒及其获得方法和应用
CN108823231B (zh) * 2018-07-09 2022-05-31 荣俊 一种猪圆环病毒3型基因工程亚单位疫苗及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7004A (en) * 1850-01-08 Connecting ctjttees to shafts of boeing instetjments
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) * 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
ATE235959T1 (de) 1994-04-15 2003-04-15 Univ Temple Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
AU4259299A (en) * 1998-05-13 1999-11-29 Innogenetics N.V. New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections
US6395472B1 (en) * 1999-02-05 2002-05-28 Abbott Laboratories Methods of utilizing the TT virus
SE9901601D0 (sv) * 1999-05-04 1999-05-04 Tripep Ab Peptides from the TT virus sequence and monospecific antibodies binding to the TT virus
CN1688606A (zh) 2002-08-12 2005-10-26 昆士兰医学研究所理事会 含有辅助t细胞和b细胞表位的新的免疫原性脂肽
CN1688605B (zh) 2002-08-12 2011-01-12 昆士兰医学研究所理事会 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽
KR20080013850A (ko) 2005-02-08 2008-02-13 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 면역원성 분자
KR20100090311A (ko) 2005-02-25 2010-08-13 화이자 프로덕츠 인크. 돼지 생식기 호흡기 증후군 바이러스의 ｎ 단백질 돌연변이체
WO2008127279A2 (en) 2006-10-05 2008-10-23 Cerebus Biologicals, Inc. Methods for treating, preventing and diagnosing porcine ttv infection
EP2356132A2 (en) * 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
RU2422536C1 (ru) * 2009-10-19 2011-06-27 Российская Федерация, от имени которой выступает Федеральное Агентство по науке и инновациям НАБОР СИНТЕТИЧЕСКИХ ОЛИГОНУКЛЕОТИДОВ ДЛЯ ВЫЯВЛЕНИЯ ДНК В КРОВИ И ДРУГИХ БИОМАТЕРИАЛАХ ВОЗБУДИТЕЛЯ ЛАТЕНТНОЙ ВИРУСНОЙ ИНФЕКЦИИ - ВИРУСА Torque teno virus СЕМЕЙСТВА Circoviridae МЕТОДОМ ПОЛИМЕРАЗНОЙ ЦЕПНОЙ РЕАКЦИИ

Also Published As

Publication number Publication date
BRPI0920248A2 (pt) 2016-01-05
KR20130126755A (ko) 2013-11-20
AU2009303845A1 (en) 2010-04-22
RU2011113442A (ru) 2012-11-27
WO2010044889A3 (en) 2010-07-22
KR101320192B1 (ko) 2013-10-30
AU2009303845B2 (en) 2013-09-12
US20140234355A1 (en) 2014-08-21
US8921535B2 (en) 2014-12-30
MX2011004053A (es) 2011-05-10
CN102256997A (zh) 2011-11-23
RU2502801C2 (ru) 2013-12-27
WO2010044889A2 (en) 2010-04-22
JP2012505653A (ja) 2012-03-08
KR20130054466A (ko) 2013-05-24
US20110064758A1 (en) 2011-03-17
US8969536B2 (en) 2015-03-03
KR20110070911A (ko) 2011-06-24
EP2356132A2 (en) 2011-08-17
CA2739469A1 (en) 2010-04-22
US20110150913A1 (en) 2011-06-23
RU2013142007A (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
BR112012008946A2 (pt) sequência polinucletídica isolada , molécula pollinucleotídica de rna, vetor ou plasmídeo , célula hospedeira , vírus a ser expresso , vacina , polipetídeo e composição de vacina
CN111088283A (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
JP2010516290A5 (pt)
JP2008056679A5 (pt)
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
JP2015502353A (ja) インフルエンザウイルスワクチンおよびその使用
BR112015010756A8 (pt) vacina de emergência baseada em peptídeo sintético contra doença do pé-e-boca (fmd)
JP6505110B2 (ja) ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用
PH12019500592A1 (en) New swine influenza vaccine
Cubillos et al. Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site
Rohde et al. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus
US20160031991A1 (en) Targeting vaccines for veterinary use
JP2012515557A5 (pt)
JP2011517938A5 (pt)
WO2023023940A1 (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN104136039A (zh) 靶向交叉呈递的树突状细胞的疫苗体
JP2015529677A5 (pt)
EA024111B1 (ru) Вакцина против вируса африканской чумы лошадей
Soria et al. Immune response and partial protection against heterologous foot‐and‐mouth disease virus induced by dendrimer peptides in cattle
CN105143251A (zh) 流感核蛋白疫苗
Mingxiao et al. Immunogenicity of plasmids encoding P12A and 3C of FMDV and swine IL-18
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
JP2013518563A5 (pt)
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
Kim et al. DNA vaccination against foot‐and‐mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: AH USA 42 LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: ZOETIS LLC (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]